Oxaliplatin and infliximab synergize to induce regression of colon cancer

DI HUANG1, JUN XUE2, SHUGUANG LI1 and DONGDONG YANG2

Departments of 1Gastrointestinal Surgical Oncology and 2Vascular and Gland Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China

Received November 16, 2016; Accepted September 13, 2017

DOI: 10.3892/ol.2017.7468

Abstract. There is currently a lack of therapeutic options for patients with advanced colon cancer. Although certain chemotherapies are able to suppress the progression slightly, the response rate is low, and side effects of treatment and tumor recurrence continue to present problems for clinicians. Tumor necrosis factor-α (TNF-α) has been identified to possess tumor-promoting properties. In the present study, the effect of anti-TNF-α treatment (infliximab) in combination with chemotherapy on colon cancer was investigated. Tumor tissue samples were collected from patients with colon cancer who received oxaliplatin (OXA) treatment. Their TNF-α expression levels were examined with regard to their sensitivity to OXA. OXA-resistant colon cancer cell lines were established to explore the effects of anti-TNF-α treatment and OXA treatment. Furthermore, an OXA-resistant colon cancer xenograft mouse model was created and the effects of the combination treatment of anti-TNF-α and OXA on the mice were assessed. The results of the present study indicated that TNF-α was increased in the tumor tissue of patients with colon cancer who were resistant to OXA and also in OXA-resistant colon cancer cell lines. Anti-TNF-α treatment using infliximab inhibited the survival of OXA-resistant colon cancer cell lines by inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity effects. The combination of infliximab and OXA treatment achieved increased efficacy on the OXA-resistant colon cancer xenograft mouse model compared with treatment with OXA alone. On the basis of the results of the present study, it was concluded that infliximab may sensitize colon cancer cells to OXA treatment.

Introduction

Colon cancer has one of the highest mortality rates of any malignant disease globally. According to the annual age-adjusted cancer incidence and mortality rate in the USA from 1975 to 2002, colon and rectal cancer were among the three most frequently diagnosed types of cancer (1). Patients with localized colon cancer and rectal cancer exhibit a high 5-year relative survival rate (>80%); however, cases exhibiting distant metastases have a 5-year relative survival rate of only ~10% (1). Previous studies have demonstrated that palliative chemotherapy is able to extend the median survival time of patients with metastatic colon cancer (2-4). However, a number of distinct effects of chemotherapies were observed among different patients with colon cancer. An increased response rate to treatment and longer continuous effects are required (3,4).

Tumor necrosis factor-α (TNF-α) is an important cytokine produced primarily by activated macrophages and numerous other cells including fibroblasts, natural killer cells and cluster of differentiation (CD)4+ lymphocytes (5,6). TNF-α exhibits multiple functions in mediating systemic inflammation, regulating the immune response, cell metabolism, proliferation and apoptosis (7,8). There are two types of TNF-α receptor (TNFRs) which mediate these complex functions: TNFR1 and TNFR2 (9,10). Previous studies have demonstrated that TNF-α serves roles in promoting the development of a number of malignant tumors, including breast, renal and pancreatic cancer (10-13). Tumor cells themselves are able to produce TNF-α (14). Anti-TNF-α treatment has been studied in a number of these tumors, and favorable effects have been observed (15).

Inflammation is associated with the initiation of colon cancer (16). Colitis-associated cancer, a subtype of colorectal cancer, is associated with inflammatory bowel disease (16). Currently anti-TNF-α treatment is used against a number of inflammatory diseases, including rheumatoid arthritis and Crohn’s disease. As TNF-α is a key pro-inflammatory cytokine, it was hypothesized that anti-TNF-α may promote the effects of chemotherapy on patients with colon cancer. In the present study, the effects of combining anti-TNF-α treatment (infliximab) and oxaliplatin (OXA) on colon cancer were explored in an animal model.

Materials and methods

Cell culture and cell line establishment. Human colon cancer cell line SW480 and murine colon cancer cell line CT-26 (American Type Culture Collection, Manassas, VA, USA) were cultured with RPMI-1640 medium (Thermo Fisher
Each slide was evaluated by two researchers independently and washed away immediately once the stain had developed. Then 3,3-diaminobenzidine was added prior to incubation at 4°C overnight. Secondary antibody (horseradish peroxidase-conjugated; 1:100 dilution; cat. no. ab6721; Abcam) was added prior to incubation for 1 h at room temperature. Then, 3,3-diaminobenzidine was added and washed away immediately once the stain had developed. After each slide was evaluated by two researchers independently without knowledge of the background information of the slides, TNF-α expression was divided into five levels based on the proportion of positive cells: 5, >80%; 4, >60%; 3, >40%; 2, >20%; 1, <20%.

Cell viability. Cell viability was determined using a Cell Counting Kit-8 (CCK-8) kit (Merck KGaA, Darmstadt, Germany), according to the manufacturer's protocol. Equal numbers of cells (5x10⁴ cells/well) were seeded on 96-well plates containing 100 µl culture medium. Various concentrations of OXA were added to the cells prior to incubation for 48 h. CCK-8 solution (10 µl/well) was added prior to incubation for 30 min at 37°C. Finally, the absorbance at 450 nm was assessed using an MRX microplate reader (Dynex Technologies, Chantilly, VA, USA). The absorbance value of each treated group relative to that of the control group was used to represent the cell viability.

Antibody-dependent cellular cytotoxicity (ADCC) assay and complement-dependent cytotoxicity (CDC) assay. ADCC and CDC assays were performed to evaluate the cytotoxic effects of infliximab on OXA-resistant colon cancer cell lines SW480-R and CT-26-R. Equal numbers of these two cell lines were seeded on 96-well plates (1x10⁵ cells/well) with 100 µl RPMI-1640 medium (Sigma-Aldrich; Merck KGaA). Infliximab (Thermo Fisher Scientific, Inc.) was added prior to incubation for 1 h at 37°C with 5% CO₂. Effector cells [macrophages were isolated from Balb/c mice as previously described (18)] were added prior to incubation for another 48 h under identical conditions. For the CDC assay, the effector cells were replaced with guinea pig serum containing mixed active complements (Sigma-Aldrich; Merck KGaA), which were added to the target cells and incubated for 5 h at 37°C with 5% CO₂. The complement was replaced with phosphate-buffered saline in the control group. The cell viability was assessed according to the aforementioned protocol.

Animal model. A colon cancer xenograft mouse model was established using the CT-26-R cell line and Balb/c mice (30 females; 20-22 g; 6 weeks of age; Shanghai Experimental Animal Center, Chinese Academy of Science, Shanghai, China). Equal numbers of CT-26-R cells (1x10⁶) were inoculated into the flanks of these mice subcutaneously. At 1 week after the inoculation, the mice were randomly divided into three groups (10 per group) to receive treatments once per week: OXA (4 mg/kg) alone; OXA (4 mg/kg) + infliximab (6 mg/kg); or saline (control). The agents were injected into the tail vein of these mice once a week. The tumor volume (width² x length x π/6) and survival date was observed and recorded. All mice were raised in a specific pathogen-free environment (at room temperature, with fresh air and a humidity of 40-50%) with a 12-h light/12-h dark cycle and free access to water and food. This animal study was approved by the Experimental Animal Use Committee of the First Affiliated Hospital of Hebei North University.

Fluorescence-activated cell sorter (FACS) analysis. FACS analysis was performed to determine the levels of TNF-α, cleaved poly(ADP-ribose) polymerase (PARP) and bromodeoxyuridine (BrdU) in colon cancer cell lines SW480, SW480-R, CT-26 and CT-26-R or xenograft mouse model-derived tumor cells. Cells were incubated with the following primary antibodies: anti-TNF-α (1:100 dilution; cat. no. ab1793; Abcam) and anti-cleaved PARP (1:100 dilution; cat. no. ab11031S; Abcam) for 30 min at room temperature followed by washing with
PBS three times. Next, a fluorescence-conjugated secondary antibody (1:1,000 dilution; cat. no. ab6789; Abcam) was added prior to incubation for 20 min at room temperature followed by washing with PBS three times. The cells were then analyzed using a BD FACSCanto™ II machine (BD Biosciences, Franklin Lakes, NJ, USA) and FlowJo software 9.7.1 (FlowJo LLC, Ashland, OR, USA).

Statistics. All statistical analysis and data visualization was performed using GraphPad 7 (GraphPad Software, Inc., La Jolla, CA, USA) or SPSS software 17.0 (SPSS, Inc., Chicago, IL, USA). The difference between means of various experimental groups were analyzed using either Student's t-test or a one-way analysis of variance with Bonferroni's pairwise comparison. Survival analysis was performed using the Kaplan-Meier estimator method. The differences between the survival curves were analyzed using a log-rank test. P<0.05 was considered to indicate a statistically significant difference.

Results

**TNF-α is increased in the tumor tissue of patients with OXA-resistant colon cancer and OXA-resistant colon cancer cell lines.** A total of 60 tumor tissue samples were collected from patients with colon cancer who accepted OXA treatment following surgery, half of whom exhibited sensitivity to the OXA treatment, with the other half exhibiting resistance to the OXA treatment. These samples were divided into two groups according to their response to the OXA treatment. IHC was performed to evaluate the TNF-α level of these tissue samples. As presented in Fig. 1A and B, these samples expressed distinct levels of TNF-α. Quantitative analysis identified that the patients with colon cancer who were sensitive to the OXA treatment had a lower mean TNF-α level compared with that of the patients who were resistant to the OXA treatment (Fig. 1C).

**TNF-α is increased in OXA-resistant colon cancer cell lines.** OXA-resistant colon cancer cell lines, CT-26-R and SW480-R, were created using low-dose OXA treatment. As presented in Fig. 2A and B, these cell lines exhibited resistance to increasing concentrations of OXA. The TNF-α expression was measured using FACS analysis (Fig. 2C and D). These cell lines exhibited increased levels of TNF-α compared with the wild-type CT-26 and SW480 cell lines. In summary, the association of TNF-α expression with OXA sensitivity suggests that TNF-α may alter the effect of chemotherapy on patients with colon cancer.

**Infliximab inhibits the survival of OXA-resistant colon cancer cell lines by inducing ADCC and CDC effects.** Considering that OXA-resistant colon cancer cell lines express increased levels of TNF-α and that TNF-α is an important cytokine which regulates the immune response, the ability of infliximab to induce ADCC and CDC effects on the OXA-resistant colon cancer cell lines CT-26-R and SW480-R was investigated. Notably, it was revealed that infliximab decreased the survival rate of CT-26-R and SW480-R cells in the presence of macrophages or active complement (Fig. 3A and B). These results suggest that TNF-α may promote the resistance of colon cancer cells to OXA treatment by inhibiting any immune response to tumor cells.
Infliximab decreases the resistance to OXA in a colon cancer mouse model. Mice bearing CT-26-R xenograft colon tumors were assigned to three treatment groups: OXA, OXA + infliximab or saline. These mice exhibited different survival rates. The group receiving OXA + infliximab exhibited the longest overall survival time and most marked tumor growth compared with the group receiving OXA alone and the control group (Fig. 4). Notably, an increased level of cleaved PARP was detected in the tumor cells of the mice treated with OXA + infliximab compared with the OXA group (Fig. 5A and B). Additionally, the BrdU incorporation rate of these tumor cells was decreased compared with that of the tumor cells from the mice receiving OXA (Fig. 5C and D).

Discussion

Although there have been previous studies demonstrating that local administration of TNF-α may inhibit the development...
of advanced solid tumors, including metastatic liver cancer and soft tissue sarcomas, only a minor effect was observed, dependent on the combination with other anti-blastic agents, including doxorubicin and melphalan (6,19,20). Conversely, previous studies have demonstrated that TNF-α may promote the metastasis of tumors (6,21). A previous study has demonstrated that TNF-α-deficient mice were resistant to chemical carcinogenesis (22). These tumor-promoting effects of TNF-α suggest that anti-TNF-α treatment may be beneficial to patients with cancer.

Anti-TNF-α treatment has been utilized previously to treat patients with myelogenous leukemia, multiple myeloma and myelofibrosis (23). There are ongoing clinical trials of anti-TNF-α treatment for other malignances, including ovarian...
cancer and non-small cell lung cancer (6,7). Additionally, TNF-α-induced protein 3 was demonstrated to inhibit the antitumor activity of CD8+ T cells, which may allow the tumor cells to evade immune surveillance (24). In the present study, it was identified that TNF-α expression was increased in the colon cell lines with induced resistance to OXA treatment. The patients with colon cancer who were resistant to OXA treatment also tended to exhibit increased TNF-α expression levels compared with the patients who were sensitive to OXA treatment. Results of the in vitro study revealed that infliximab induced ADCC and CDC effects, inhibiting the survival of OXA-resistant colon cancer cell lines. In the CT-26-R xenograft mouse model, the combination treatment of infliximab and OXA resulted in improved effects when compared with the OXA treatment alone.

In previous studies, to the best of our knowledge, there was no evidence demonstrating the direct cytotoxicity caused by anti-TNF-α treatment. The present study provided a possible explanation of the tumor-inhibiting effects of anti-TNF-α treatment: Anti-TNF-α treatment may reject tumor cells through immune response-dependent methods, i.e., ADCC and CDC effects. The combination of infliximab and OXA achieved apparent favorable effects in the OXA-resistant colon cancer xenograft mouse model. This suggests that the anti-TNF-α treatment may have increased the sensitivity of colon cancer cells to chemotherapy. Furthermore, increased levels of cleaved PARP and the decreased BrdU incorporation level were also observed in the infliximab- and OXA-treated mice, which suggested that the combining treatment effectively induced apoptosis and inhibited the proliferation of colon cancer cells.

In conclusion, we hypothesize that anti-TNF-α treatment may sensitize colon cancer cells to chemotherapy and thus enhance the efficacy of chemotherapy for the treatment of colon cancer.

Acknowledgements

The present study sponsored by the Excellent Clinical Medicine Talent Program of Finance Department of Hebei Province, 2015: Fundamental and Clinical Research of Gene Detection, Mechanism, Resistance and Accurate Treatment of Colorectal Cancer Cases in Regions of Hebei, Shanxi and Inner Mongolia.

References

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Jonker DJ, Maroun JA and Kocha W: Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized controlled trials. Br J Cancer 82: 1789-1794, 2000.
3. Köhne CH, Cunningham D, Di Costanzo F, Gilmeilus B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, et al.: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308-317, 2002.
4. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernerio J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004.
5. Eisenman ST, Gibbons SJ, Verhulst PJ, Cipriani G, Saur D and Farrugia G: Tumor necrosis factor alpha derived from classically activated ‘M1’ macrophages reduces interstitial cell of Cajal numbers. Neurogastroenterol Motil 27: 27, 2015.
6. Mocellin S, Rossi CR, Pilati P and Nitti D: Tumor necrosis factor, cancer and antinecrosis therapy. Cytokine Growth Factor Rev 16: 35-53, 2005.
7. van Horssen R, Ten Hagen TL and Eggemont AM: TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408, 2006.
8. Wu Y and Zhou BP: TNF-alpha/NF-kappaB/Smad pathway in cancer cell migration and invasion. Br J Cancer 102: 639-644, 2010.
9. Chen G and Goeddel DV: TNF-R1 signaling: A beautiful pathway. Science 296: 1634-1635, 2002.
10. Sedger LM and McDermott MF: TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev 25: 453-472, 2014.
11. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG and Roberts AB: Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 118: 2143-2153, 2005.
12. Harrison ML, Oebelmüller E, Maiese NR, Hoare S, Edmonds K, Li MF, Chao D, Hall K, Lee C, Timothéoudou E, et al.: Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential Phase II trials of infliximab at standard and high dose. J Clin Oncol 25: 4542-4549, 2007.
13. Ohri CM, Shikotra A, Green RH, Waller DA and Bradling P: Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 10: 323, 2010.
14. Sethi G, Sung B and Aggarwal BB: TNF: A master switch for inflammation to cancer. Front Biosci 13:5094-5107, 2008.
15. Terzic J, Grivennikov S, Karin E and Karin M: Inflammation and cancer. Gastroenterology 138: 2101-2114.e5, 2010.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
17. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Fujii Y, Yamasaki S, Beyaert R, van den Brule A, et al.: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Cancer Res 69: 453-461, 2009.
18. Ray A and Dittel BN: Isolation of mouse peritoneal cavity cells. J Vis Exp: pii:14888, 2010.
19. Rossi CR, Follette M, Pilati P, Mocellin S and Lise M: Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 29: 400-409, 2002.
20. Christoforidis D, Martinet O, Lejeune FJ and Mosimann F: Isolated liver perfusion for non-resectable liver tumours: A review. Eur J Surg Oncol 28: 875-890, 2002.
21. Orosz P, Echtenacher B, Falk W, Rüschoff J, Weber D and Müller DN: Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177: 1391-1398, 1993.
22. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E and Fujiki H: Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59: 4516-4518, 1999.
23. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M and Giles FF: Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNF alpha levels during treatment. Leuk Res 27: 375-380, 2003.
24. Giordano M, Roncagalli R, Bourdel P, Chasson L, Buter M, Yamasaki S, Beyaert R, van den Brule A, et al.: From mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev 25: 453-472, 2014.